AB Science receives regulatory approval from european countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML

30/07/2025 – AB Science today announced the approval of the third of four stages of the Phase I/II study with the compound AB8939 in adult patients with relapsed/refractory acute myeloid leukemia